Clinical Scorecard: Link Between Reduced Serum Sclerostin Concentrations and Higher Arterial Stiffness Risk: Insights from the JPOS Cohort Analysis
At a Glance
Category
Detail
Condition
Increased arterial stiffness associated with lower serum sclerostin levels
Key Mechanisms
Sclerostin inhibits Wnt/β-catenin pathway affecting bone formation and vascular endothelium; lower sclerostin linked to increased arterial stiffness
Target Population
Japanese community-dwelling women aged ≥ 50 years
Care Setting
Community-based longitudinal cohort study with clinical follow-up
Key Highlights
Lower serum sclerostin levels are longitudinally associated with increased risk of arterial stiffness measured by brachial-ankle pulse wave velocity (baPWV).
The study excluded women with baseline baPWV ≥ 1800 cm/s, a threshold for high cardiovascular risk, focusing on progression over 4-5 years.
Adjusted odds ratio for increased arterial stiffness was significantly higher in the lowest sclerostin tertile (OR 2.50, P = .014) after controlling for multiple cardiovascular risk factors.
Guideline-Based Recommendations
Diagnosis
Use brachial-ankle pulse wave velocity (baPWV) measurement to assess arterial stiffness, with ≥1800 cm/s indicating increased stiffness and cardiovascular risk.
Management
Consider monitoring serum sclerostin levels as a potential biomarker for arterial stiffness risk in postmenopausal women.
Be cautious with anti-sclerostin antibody therapies (e.g., romosozumab) due to potential cardiovascular risks.
Monitoring & Follow-up
Longitudinal follow-up of baPWV values to detect progression of arterial stiffness.
Regular assessment of cardiovascular risk factors including hypertension, hyperlipidemia, diabetes mellitus, and renal function.
Risks
Anti-sclerostin antibody treatment may increase cardiovascular disease risk; cardiovascular safety should be evaluated in patients receiving such therapies.
Patient & Prescribing Data
Postmenopausal Japanese women aged ≥ 50 years without baseline increased arterial stiffness
Lower serum sclerostin levels correlate with higher risk of arterial stiffness; anti-sclerostin therapies require cardiovascular risk consideration.
Clinical Best Practices
Measure baPWV to identify patients at risk for increased arterial stiffness and cardiovascular events.
Interpret serum sclerostin levels in the context of cardiovascular risk assessment, especially in postmenopausal women.
Adjust for confounding factors such as age, BMI, hypertension, hyperlipidemia, diabetes, renal function, and bone mineral content when evaluating arterial stiffness risk.
Exercise caution when prescribing anti-sclerostin antibodies due to potential cardiovascular adverse effects.
